|
|
ApoVax-SVN as a Novel Vaccine for Cancer Immunotherapy
|
1R41CA121665-01A2
|
$328,300
|
$328,300
|
Shirwan, Haval
|
APOIMMUNE, INC
|
|
|
Effect of VDJ Recombination on Scid B Cell Development
|
3R01CA073857-09S1
|
$1,334
|
$1,334
|
CHANG, YUNG
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Effect of VDJ Recombination on Scid B Cell Development
|
3R01CA073857-09S2
|
$45,598
|
$45,598
|
CHANG, YUNG
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Effect of VDJ Recombination on Scid B Cell Development
|
5R01CA073857-09
|
$222,001
|
$222,001
|
CHANG, YUNG
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Targeted Gene Therapy for Lymphoma
|
5R01CA113454-02
|
$254,310
|
$254,310
|
SMITH, BRUCE
|
AUBURN UNIVERSITY AT AUBURN
|
|
|
Bay Area Tumor Institute CCOP
|
2U10CA045461-18
|
$480,000
|
$9,600
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
|
SV40 Pathogenesis of Human Infections
|
5R01CA104818-04
|
$464,495
|
$185,798
|
BUTEL, JANET
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
SPORE in Lymphoma
|
1P50CA126752-01
|
$2,266,618
|
$1,133,309
|
Heslop, Helen
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Role of PML nuclear body proteins for establishment of EBV latent infection
|
5R01CA124309-02
|
$258,530
|
$258,530
|
Ling, Paul
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
1P30CA125123-01
|
$1,500,000
|
$45,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-01S1
|
$111,700
|
$3,351
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Novel Strategies for Immunotherapy fo Cancer
|
5R01CA101795-04
|
$263,284
|
$157,970
|
Wang, Rongfu
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Virginia Mason Community Clinical Oncology Program
|
3U10CA035192-24S1
|
$80,000
|
$1,600
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-24
|
$391,000
|
$7,820
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
Training Patients and Partners for HSCT: A Novel Coping Skills Intervention
|
1R03CA130725-01
|
$84,500
|
$42,250
|
Lawsin, Catalina
|
BERNARD M. BARUCH COLLEGE
|
|
|
Eastern Cooperative Oncology Group
|
2U10CA080775-09
|
$128,678
|
$7,721
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Multistep Lymphomagenesis/Tumorigenesis in Transgenic Mice: Protein Kinase Ck2
|
5R01CA071796-10
|
$275,767
|
$137,884
|
SELDIN, DAVID
|
BOSTON MEDICAL CENTER
|
|
|
Regulation of apoptosis by PI 3-kinase/Akt signaling
|
5R01CA018689-31
|
$457,492
|
$45,749
|
COOPER, GEOFFREY
|
BOSTON UNIVERSITY
|
|
|
Transformation of Cells by the REL Oncogene
|
5R01CA047763-20
|
$275,637
|
$275,637
|
GILMORE, THOMAS
|
BOSTON UNIVERSITY
|
|
|
Proteomic biomarkers for lymphoma
|
1R03CA128006-01
|
$81,250
|
$81,250
|
DENIS, GERALD
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
C-MYC EXPRESSION AND APOPTOSIS IN B CELLS
|
5R01CA036355-22
|
$287,887
|
$143,944
|
SONENSHEIN, GAIL
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Role of P80 pro-IL-16 in T Cell Malignancy
|
5R01CA100925-03
|
$282,526
|
$141,263
|
ZHANG, YUJUN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Epstein-Barr Virus Nuclear Proteins in B Cell Growth Transformation
|
2R01CA047006-20A2
|
$538,386
|
$269,193
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
SPORE in Skin Cancer
|
3P50CA093683-05S2
|
$512,285
|
$102,457
|
KUPPER, THOMAS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Aspartame Intake and the Risk of Cancer
|
1R03CA130054-01
|
$116,101
|
$38,313
|
SCHERNHAMMER, EVA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Pathogenesis of Epstein-Barr Virus Infection
|
5R01CA068051-12
|
$403,843
|
$282,690
|
WANG, FREDERICK
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
CCOP Research Base, PCPT/PCPT LTFU, and SELECT Programs
|
2U10CA037429-22
|
$14,335,283
|
$716,764
|
Coltman, Charles
|
CANCER THERAPY AND RESEARCH CENTER
|
|
|
Long Circulating Targeted Nanoparticles for non-Hodgkin's Lymphoma Treatment
|
1R43CA130381-01
|
$153,437
|
$153,437
|
Fong, Peter
|
CARIGENT THERAPEUTICS
|
|
|
Carle Cancer Center Community Clinical Oncology Program
|
3U10CA035195-24S1
|
$120,000
|
$1,200
|
ROWLAND, KENDRITH
|
CARLE CLINIC ASSOCIATION, P C
|
|
|
Carle Cancer Center Community Clinical Oncology Program
|
5U10CA035195-24
|
$693,116
|
$6,931
|
ROWLAND, KENDRITH
|
CARLE CLINIC ASSOCIATION, P C
|
|
|
Eastern Cooperative Oncology Group Studies
|
5U10CA014548-33
|
$413,938
|
$24,836
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Non-natural Nucleoside Inhibitors of DNA Polymerases
|
5R01CA118408-03
|
$229,214
|
$114,607
|
BERDIS, ANTHONY
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Multicenter Trial of O6BG and Topical BCNU for CTCL
|
5R21CA115057-02
|
$286,763
|
$286,763
|
COOPER, KEVIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Mechanism of Steroid Action in Lymphoid Malignancy
|
5R01CA042755-21
|
$311,299
|
$155,650
|
DISTELHORST, CLARK
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
CWRU/UHICC Phase I Trials of Anticancer Agents
|
5U01CA062502-14
|
$560,898
|
$5,609
|
DOWLATI, AFSHIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-18
|
$5,104,000
|
$255,200
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Molecular Targeting of Bcl-xL Pathway in Cancer
|
5R01CA109181-04
|
$265,033
|
$66,258
|
HALDAR, SUBRATA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Cedar Rapids Oncology Project
|
5U10CA052352-18
|
$423,530
|
$4,235
|
WIESENFELD, MARTIN
|
CEDAR RAPIDS ONCOLOGY PROJECT
|
|
|
C-N-, and L-MYC Effects on Hematopoietic Cells
|
5R01CA078259-08
|
$231,309
|
$231,309
|
Prochownik, Edward
|
CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS
|
|
|
RhoH GTPase in Hematopoiesis and Cancer
|
5R01CA113969-03
|
$279,026
|
$69,757
|
WILLIAMS, DAVID
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
|
|
Rac GTPases as Targets in Lymphomagenesis
|
1R01CA125658-01
|
$285,000
|
$142,500
|
ZHENG, YI
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
|
|
Targeting RhoA Lymphomagenesis
|
5R03CA125830-02
|
$72,825
|
$72,825
|
ZHENG, YI
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
|
|
Molecular Pathways in Suppression and Development of T Lineage Lymphomas
|
1R01CA125195-01A1
|
$313,500
|
$313,500
|
BASSING, CRAIG
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
|
USE OF mTOR INHIBITORS IN B CELL LEUKEMIA
|
5R01CA102646-03
|
$308,531
|
$101,815
|
GRUPP, STEPHAN
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
|
PSYCHOLOGICAL OUTCOME IN CHILDHOOD CANCER SURVIVORS
|
5R01CA106928-04
|
$352,545
|
$35,255
|
KAZAK, ANNE
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
|
Delaware/Christiana Care CCOP
|
2U10CA045418-21
|
$835,003
|
$8,350
|
GRUBBS, STEPHEN
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
|
Delaware/Christiana Care CCOP
|
3U10CA045418-21S1
|
$119,011
|
$1,190
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
|
City of Hope Lymphoma SPORE
|
5P50CA107399-04
|
$2,163,323
|
$1,081,662
|
FORMAN, STEPHEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
3U10CA046368-20S1
|
$32,200
|
$3,220
|
MARGOLIN, KIM
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
5U10CA046368-20
|
$326,504
|
$32,650
|
MARGOLIN, KIM
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Total relevant funding to Non Hodgkins lymphoma for this search: $112,959,162
|
